Debate: Should the dose or duration of anticoagulants for the prevention of venous thrombosis be increased in patients with COVID-19 while we are awaiting the results of clinical trials?

Gomez, Keith; Laffan, Mike; Bradbury, Charlotte

Gomez, Keith; Laffan, Mike; Bradbury, Charlotte.

Gomez K; Haemophilia Centre and Thrombosis Unit, Royal Free Hospital London NHS Foundation Trust, London, UK.
Laffan M; Department of Immunity and Inflammation, Centre for Haematology, Faculty of Medicine, Imperial College London, London, UK.
Bradbury C; Faculty of Translational Health Sciences, University of Bristol, Bristol, UK.

Br J Haematol ; 192(3): 459-466, 2021 02.

Article in English | MEDLINE | ID: covidwho-966798

Subject(s)

Anticoagulants/administration & dosage; COVID-19/complications; SARS-CoV-2; Venous Thrombosis/prevention & control; COVID-19/virology; Clinical Decision-Making; Clinical Trials as Topic; Disease Management; Disease Susceptibility; Duration of Therapy; Humans; Venous Thrombosis/etiology

Keywords

anticoagulation; clinical trials; coronavirus disease 2019; thromboprophylaxis; venous thrombosis

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Venous Thrombosis / SARS-CoV-2 / COVID-19 / Anticoagulants Type of study: Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Br J Haematol Year: 2021 Document Type: Article Affiliation country: Bjh.17241

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google